Neuroendocrine Neoplasm Based on Multi-omics Integrated Analysis

NCT04931446 | Unknown DMC

• 1 other identifier: CSPAC-NEN-2
• Study Type: observational
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

This project intends to analyze the molecular biological characteristics of NEN based on multi-omics, develop an exclusive NEN multi-omics big data platform, and carry out molecular subtypes and potential targets prediction, so as to improve the therapeutic effect of neuroendocrine tumors.

Conditions

Neuroendocrine Neoplasm

Keywords

Neuroendocrine Neoplasm; Multi-omics Analysis; Molecular Subtypes

Outcome Measures

Primary Outcomes (1)

• NEN mechanism analysis based on Multi-omics

  Collect NEN tissue specimens and peripheral blood specimens for genomics, transcriptomics, proteomics, phosphorylation, metabolomics and other multiple omics sequencing analysis, so as to find the relationship between these molecular omics and phenotypes, explore NEN mechanism, including driver genes, activation of signal pathways, etc., and screen sensitive drugs based on potential targets. Use multi-omics data to establish NEN big data analysis platform, including sensitive target prediction, related gene prediction, survival analysis, and so on.

  One year

Secondary Outcomes (1)

• NEN immune microenvironment analysis

  One year

Study Arms (1)

Gastroenteropancreatic neuroendocrine neoplasms

Procedure: Biopsy/surgical tissue and peripheral blood

Interventions

Biopsy/surgical tissue and peripheral blood PROCEDURE

Retrieve specimens stored in the tissue bank, the main types of samples are RNAlater specimens, liquid nitrogen frozen specimens and peripheral blood specimens

Gastroenteropancreatic neuroendocrine neoplasms

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Collect gastrointestinal pancreatic neuroendocrine tumor samples stored in the tissue bank of Fudan University Affiliated Tumor Hospital from January 31, 2010 to March 31, 2021

You may qualify if:

• Received surgical treatment at Fudan University Affiliated Cancer Hospital from January 2010 to January 2021;
• Postoperative pathology proved to be neuroendocrine tumor;
• Has signed an informed consent form for tissue bank sample collection, agreeing to use the specimens and related clinical data for scientific research.

You may not qualify if:

• Merge other malignant tumors;
• The clinical data is missing.

Sponsors & Collaborators

• Xian-Jun Yu: lead

Study Sites (1)

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University

Shanghai, Shanghai Municipality, 200032, China

Location

Related Publications (12)

• Alizadeh AA, Aranda V, Bardelli A, Blanpain C, Bock C, Borowski C, Caldas C, Califano A, Doherty M, Elsner M, Esteller M, Fitzgerald R, Korbel JO, Lichter P, Mason CE, Navin N, Pe'er D, Polyak K, Roberts CW, Siu L, Snyder A, Stower H, Swanton C, Verhaak RG, Zenklusen JC, Zuber J, Zucman-Rossi J. Toward understanding and exploiting tumor heterogeneity. Nat Med. 2015 Aug;21(8):846-53. doi: 10.1038/nm.3915.

  PMID: 26248267 BACKGROUND

• Hausser J, Alon U. Tumour heterogeneity and the evolutionary trade-offs of cancer. Nat Rev Cancer. 2020 Apr;20(4):247-257. doi: 10.1038/s41568-020-0241-6. Epub 2020 Feb 24.

  PMID: 32094544 BACKGROUND

• Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012 Jul 18;487(7407):330-7. doi: 10.1038/nature11252.

  PMID: 22810696 BACKGROUND

• Lehmann BD, Jovanovic B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One. 2016 Jun 16;11(6):e0157368. doi: 10.1371/journal.pone.0157368. eCollection 2016.

  PMID: 27310713 BACKGROUND

• Halaburkova A, Cahais V, Novoloaca A, Araujo MGDS, Khoueiry R, Ghantous A, Herceg Z. Pan-cancer multi-omics analysis and orthogonal experimental assessment of epigenetic driver genes. Genome Res. 2020 Oct;30(10):1517-1532. doi: 10.1101/gr.268292.120. Epub 2020 Sep 22.

  PMID: 32963031 BACKGROUND

• Taber A, Christensen E, Lamy P, Nordentoft I, Prip F, Lindskrog SV, Birkenkamp-Demtroder K, Okholm TLH, Knudsen M, Pedersen JS, Steiniche T, Agerbaek M, Jensen JB, Dyrskjot L. Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. Nat Commun. 2020 Sep 25;11(1):4858. doi: 10.1038/s41467-020-18640-0.

  PMID: 32978382 BACKGROUND

• Sailem HZ, Bakal C. Identification of clinically predictive metagenes that encode components of a network coupling cell shape to transcription by image-omics. Genome Res. 2017 Feb;27(2):196-207. doi: 10.1101/gr.202028.115. Epub 2016 Nov 18.

  PMID: 27864353 BACKGROUND

• Su H, Shen Y, Xing F, Qi X, Hirshfield KM, Yang L, Foran DJ. Robust automatic breast cancer staging using a combination of functional genomics and image-omics. Annu Int Conf IEEE Eng Med Biol Soc. 2015;2015:7226-9. doi: 10.1109/EMBC.2015.7320059.

  PMID: 26737959 BACKGROUND

• Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, Kwekkeboom D, Lau WY, Klersy C, Vilgrain V, Davidson B, Siegler M, Caplin M, Solcia E, Schilsky R; Working Group on Neuroendocrine Liver Metastases. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014 Jan;15(1):e8-21. doi: 10.1016/S1470-2045(13)70362-0.

  PMID: 24384494 BACKGROUND

• Mayo SC, de Jong MC, Pulitano C, Clary BM, Reddy SK, Gamblin TC, Celinksi SA, Kooby DA, Staley CA, Stokes JB, Chu CK, Ferrero A, Schulick RD, Choti MA, Mentha G, Strub J, Bauer TW, Adams RB, Aldrighetti L, Capussotti L, Pawlik TM. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol. 2010 Dec;17(12):3129-36. doi: 10.1245/s10434-010-1154-5. Epub 2010 Jun 29.

  PMID: 20585879 BACKGROUND

• Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T, Anlauf M, Wiedenmann B, Salazar R; Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157-76. doi: 10.1159/000335597. Epub 2012 Feb 15. No abstract available.

  PMID: 22262022 BACKGROUND

• Rindi G, D'Adda T, Froio E, Fellegara G, Bordi C. Prognostic factors in gastrointestinal endocrine tumors. Endocr Pathol. 2007 Fall;18(3):145-9. doi: 10.1007/s12022-007-0020-x.

  PMID: 18058263 BACKGROUND

MeSH Terms

Conditions

Neuroendocrine Tumors

Interventions

Biopsy

Condition Hierarchy (Ancestors)

Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue

Intervention Hierarchy (Ancestors)

Cytodiagnosis; Cytological Techniques; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Specimen Handling; Diagnostic Techniques, Surgical; Surgical Procedures, Operative; Investigative Techniques

Study Officials

• Xianjun Yu, MD, PhD

  Fudan University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Xianjun Yu, MD, PhD

CONTACT

+86-13801669875; yuxianjun@fudanpci.org

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: President of Shanghai Pancreatic Cancer Institute

Study Record Dates

• First Submitted: June 2, 2021
• First Posted: June 18, 2021
• Study Start: July 1, 2021
• Primary Completion: March 1, 2022
• Study Completion: December 1, 2022
• Last Updated: June 18, 2021

Record last verified: 2021-06

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)